1.Molecular mechanisms involved in human platelet aggregation by synergistic interaction of platelet-activating factor and 5-hydroxytryptamine..
Bukhtiar H SHAH ; Huma RASHEED ; Ibrahim H RAHMAN ; Amir H SHARIFF ; Fatima L KHAN ; Hina B RAHMAN ; Sara HANIF ; Sheikh A SAEED
Experimental & Molecular Medicine 2001;33(4):226-233
Our recent studies have shown that co-activation of Gq and Gi proteins by 5-hydroxytryptamine (5-HT) and adrenaline show synergism in human platelet aggregation. This study was conducted to examine the mechanism(s) of synergistic interaction of 5-HT and platelet activating factor (PAF) in human platelets. We show that PAF, but not 5-HT, increased platelet aggregation in a concentration-dependent manner. However, low concentrations of 5-HT (2 microM) potentiated platelet aggregation induced by subthreshold concentration of PAF (40 nM) indicating a synergistic interaction between the two agonists and this synergism was blocked by receptor antagonists to either 5-HT or PAF. 5-HT also potentiated the effect of PAF on thromboxane A2 (TXA2) formation and phosphorylation of extracellularly regulated mitogen-activated protein kinases (ERK1/2). The synergism of 5-HT and PAF in platelet aggregation was inhibited by calcium (Ca2+) channel blockers, verapamil and diltiazem, phospholipase C (PLC) inhibitor, U73122, cyclooxygenase (COX) inhibitor, indomethacin, and MEK inhibitor, PD98059. These data suggest that synergistic effect of 5-HT and PAF on human platelet aggregation involves activation of PLC/Ca2+, COX and MAP kinase pathways.
Diltiazem/pharmacology
;
Dose-Response Relationship, Drug
;
Drug Synergism
;
Estrenes/pharmacology
;
Flavones/pharmacology
;
Human
;
In Vitro
;
Indomethacin/pharmacology
;
Kinetics
;
Mitogen-Activated Protein Kinases/metabolism
;
Phosphorylation/drug effects
;
Platelet Activating Factor/*pharmacology
;
Platelet Activation/drug effects
;
Platelet Aggregation/*drug effects/physiology
;
Pyrrolidinones/pharmacology
;
Serotonin/*pharmacology
;
Thromboxane A2/biosynthesis
;
Verapamil/pharmacology
2.Molecular mechanisms involved in human platelet aggregation by synergistic interaction of platelet-activating factor and 5-hydroxytryptamine..
Bukhtiar H SHAH ; Huma RASHEED ; Ibrahim H RAHMAN ; Amir H SHARIFF ; Fatima L KHAN ; Hina B RAHMAN ; Sara HANIF ; Sheikh A SAEED
Experimental & Molecular Medicine 2001;33(4):226-233
Our recent studies have shown that co-activation of Gq and Gi proteins by 5-hydroxytryptamine (5-HT) and adrenaline show synergism in human platelet aggregation. This study was conducted to examine the mechanism(s) of synergistic interaction of 5-HT and platelet activating factor (PAF) in human platelets. We show that PAF, but not 5-HT, increased platelet aggregation in a concentration-dependent manner. However, low concentrations of 5-HT (2 microM) potentiated platelet aggregation induced by subthreshold concentration of PAF (40 nM) indicating a synergistic interaction between the two agonists and this synergism was blocked by receptor antagonists to either 5-HT or PAF. 5-HT also potentiated the effect of PAF on thromboxane A2 (TXA2) formation and phosphorylation of extracellularly regulated mitogen-activated protein kinases (ERK1/2). The synergism of 5-HT and PAF in platelet aggregation was inhibited by calcium (Ca2+) channel blockers, verapamil and diltiazem, phospholipase C (PLC) inhibitor, U73122, cyclooxygenase (COX) inhibitor, indomethacin, and MEK inhibitor, PD98059. These data suggest that synergistic effect of 5-HT and PAF on human platelet aggregation involves activation of PLC/Ca2+, COX and MAP kinase pathways.
Diltiazem/pharmacology
;
Dose-Response Relationship, Drug
;
Drug Synergism
;
Estrenes/pharmacology
;
Flavones/pharmacology
;
Human
;
In Vitro
;
Indomethacin/pharmacology
;
Kinetics
;
Mitogen-Activated Protein Kinases/metabolism
;
Phosphorylation/drug effects
;
Platelet Activating Factor/*pharmacology
;
Platelet Activation/drug effects
;
Platelet Aggregation/*drug effects/physiology
;
Pyrrolidinones/pharmacology
;
Serotonin/*pharmacology
;
Thromboxane A2/biosynthesis
;
Verapamil/pharmacology
3.Gender as a Risk Factor in Relationship between Trauma Exposure and Mental Health Symptoms among Journalists
Sara Fatima Malik ; Jamil A. Malik ; Rubina Hanif
ASEAN Journal of Psychiatry 2022;23(no. 3):1-7
Mental health symptoms are more likely to develop among professionals providing services to traumatized populations. Persistent exposure of tragedies and life-threatening events would presumably have a negative impact on psychological health. The present study investigates the role of gender as a risk factor among professionals that may influence the ontogeny of stress symptoms. It is hypothesized that females working in journalism are at higher risk to develop depression, anxiety, and PTSS. The Sample included media professionals from Lahore and the capital territory of Islamabad, age ranging from 20 to 61 years. The mean age of media professionals was 34.21 (SD=8.21) years. Data was collected from both male (n=440) and females (n=185) participants from different media houses and press clubs. Along with a detailed demographic sheet, data was collected on the Journalist Traumatic Exposure Scale and Depression, Anxiety, Stress Scale. T-values showed significant gender differences on depression (t=-2.54, p<.01) and females scored higher than male counterparts on depression. Moderation result illustrated that gender positively moderated the effect of trauma exposure on stress, anxiety, depression of journalists (B interaction=0.12, 0.11, 0.16 respectively; p<0.01) explaining 21% variance (R2=0.21). Though an increase in trauma exposure increases stress, anxiety, and depression of both male and female journalists; however, females are at a higher risk to develop mental health symptoms due to exposure to traumatic events. Coping strategies (e.g., offering trainings, professional development on trauma reporting, etc.) are recommended to promote the well-being of journalists